IM Cannabis Corp. (IMCC) Fair Value 2026

IMCC · Medicinal Chemicals & Botanical Products ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

4.6 /10

32 fundamental signals · 2 models active

Value Trap Risk

WARN (40/100)

Quick Summary — As of 2026-07-15, IM Cannabis Corp. (IMCC) trades at $0.15. QOC: 4.6/10. Value Trap Risk: 40/100 (WARN). 2/13 models active.

Key Facts

Ticker
IMCC
Price
$0.15
Quality Score
4.6/10
Value Trap Risk
40/100
Models Active
2/13
Last Updated
Strength: PWERM suggests +135.8% upside with 38% confidence
Risk: Value Trap score of 40 suggests caution despite apparent undervaluation

Is IM Cannabis Corp. (IMCC) Undervalued or Overvalued in 2026?

According to CirclFi’s 2-model valuation engine, IM Cannabis Corp. (IMCC) appears undervalued as of : the median of 2 independent fair value estimates is $0.20, 33.8% above the current price of $0.15. Estimates range from $0.05 to $0.35. IMCC scores 4.6/10 on fundamental quality and 40/100 on value-trap risk.

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy IM Cannabis Corp. Stock in 2026? →

Valuation Matrix

2 Intrinsic Value Models vs. Current Price ($0.15)

Core Models (Unlocked)
Model Fair Value Upside
ML-RIV
Medium Conviction
 $0.05 -68.1%
PWERM
Medium Conviction
 $0.35 +135.8%

All Models Active

All 2 models are displayed above.

What Is IM Cannabis Corp. (IMCC) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, IM Cannabis Corp. presents a highly debated valuation profile at its current price of $0.15. The composite intrinsic value is estimated at $0.20 (+33.8% average upside), masking a wide model spread between the 1 bullish models and 1 bearish models. Model dispersion is worth noting: PWERM targets $0.35 (+135.8%), versus ML-RIV at $0.05 (-68.1%). This +203.8% range highlights the importance of multi-model analysis rather than relying on any single methodology.

What Do the Models Say About IMCC?

2 of 13 models are currently active for IMCC. Of these, 1 model suggests upside while 1 model suggests overvaluation. See which stocks rank higher →

How Does IMCC Rank in Medicinal Chemicals & Botanical Products?

Among 17 Medicinal Chemicals & Botanical Products stocks, IMCC ranks #12 by Quality of Company score. CirclFi's QOC score of 4.6/10 evaluates 32 fundamental signals. A score of 4.6 reflects mixed fundamentals.

IM Cannabis Corp.'s positioning within the Medicinal Chemicals & Botanical Products segment means that margin expansion trajectory plays an outsized role in fundamental analysis. The sector's unique characteristics — including reshoring and supply chain localization — shape both the opportunity set and risk profile.

Is IMCC a Value Trap?

CirclFi's Value Trap algorithm assigns IMCC a score of 40/100 (WARN). This is a warning signal. Additional research into recent 10-Q filings is recommended. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

2 of 13 models are active for IM Cannabis Corp.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, IM Cannabis Corp. earns a quality score of 4.6/10. This mixed rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency. Our Value Trap detector shows moderate caution signals worth monitoring.

The gap between the most bullish and bearish model spans +203.8% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every IMCC valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across IMCC's 2 active models, average confidence is 40%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy IM Cannabis Corp. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Medicinal Chemicals & Botanical Products Stocks Should You Also Analyze?

8 related Medicinal Chemicals & Botanical Products stocks with 13-model coverage

NAGENiagen Bioscience, Inc.QOC 9.1FTLFFitLife Brands, Inc.QOC 9.1USNAUSANA Health Sciences, Inc.QOC 7.6BTMDBiote Corp.QOC 6.7TLRYTilray Brands, Inc.QOC 6.4MTEXMannatech, IncorporatedQOC 6.3NAIINatural Alternatives InternatioQOC 6.2SNYRSynergy CHC Corp.QOC 5.8

Read investment analysis: NAGE · FTLF · USNA · BTMD · TLRY

Frequently Asked Questions About IM Cannabis Corp.

What is IM Cannabis Corp.'s intrinsic value in 2026?

Based on CirclFi's 13-model analysis, IM Cannabis Corp. (IMCC) has multiple fair value estimates. The Bayesian DCF model runs 10,000 Monte Carlo simulations with jump-diffusion to estimate intrinsic value. The Quality of Company score is 4.6/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is IMCC overvalued or undervalued right now?

At $0.15, 1 of 2 active models suggest IMCC may be undervalued, while 1 indicate potential overvaluation. The median of all 2 fair value estimates is $0.20, 33.8% above the current price of $0.15 — a consensus view that IMCC is undervalued. The assessment depends on which methodology best fits IM Cannabis Corp.'s business model in Medicinal Chemicals & Botanical Products.

What does a Quality of Company score of 4.6 mean for IMCC?

IM Cannabis Corp.'s QOC of 4.6/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on IMCC?

CirclFi analyzes IMCC with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 2 of 13 are active for this stock. Read the full methodology →

Is IMCC a value trap in 2026?

IM Cannabis Corp.'s Value Trap score is 40/100 (WARN). This elevated score suggests the stock may look undervalued but faces deteriorating fundamentals — declining margins, rising debt, or shrinking revenue could make the apparent discount deceptive. Browse our ranked stock lists to compare value-trap scores across industries. Browse stocks by value-trap risk →

Cite this analysis — “According to CirclFi’s 2-model valuation engine, IM Cannabis Corp. (IMCC) has a median fair value of $0.20 — 33.8% above the current price of $0.15 — as of 2026-07-15.” Source: circlfi.com/stock/IMCC/ · Methodology